APS vs. PLI, ABCN, EMC, FRX, BCT, IPA, SCYB, COM, NVH, and IGX
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry.
Aptose Biosciences vs.
Aptose Biosciences (TSE:APS) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Given ProMetic Life Sciences' higher possible upside, analysts plainly believe ProMetic Life Sciences is more favorable than Aptose Biosciences.
15.1% of Aptose Biosciences shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ProMetic Life Sciences received 229 more outperform votes than Aptose Biosciences when rated by MarketBeat users. However, 72.20% of users gave Aptose Biosciences an outperform vote while only 67.69% of users gave ProMetic Life Sciences an outperform vote.
Aptose Biosciences' return on equity of 1,017.48% beat ProMetic Life Sciences' return on equity.
In the previous week, Aptose Biosciences had 1 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 1 mentions for Aptose Biosciences and 0 mentions for ProMetic Life Sciences. Aptose Biosciences' average media sentiment score of 1.16 beat ProMetic Life Sciences' score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the media.
Aptose Biosciences has higher earnings, but lower revenue than ProMetic Life Sciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Aptose Biosciences beats ProMetic Life Sciences on 10 of the 15 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
This page (TSE:APS) was last updated on 3/30/2025 by MarketBeat.com Staff
